(Q33596863)

28 July 2017

2 references

7 February 2024

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (English)

1 reference

28 July 2017

Lars L Gustafsson

16

0 references

Ott Laius

7

object named as

Ott Laius

1 reference

28 July 2017

9

Catherine Sermet

1 reference

28 July 2017

Jakub Adamski

1

1 reference

28 July 2017

Brian Godman

2

1 reference

28 July 2017

Gabriella Ofierska-Sujkowska

3

1 reference

28 July 2017

Bogusława Osińska

4

1 reference

28 July 2017

Harald Herholz

5

1 reference

28 July 2017

Kamila Wendykowska

6

1 reference

28 July 2017

Saira Jan

8

1 reference

28 July 2017

Corrine Zara

10

1 reference

28 July 2017

Marija Kalaba

11

1 reference

28 July 2017

Roland Gustafsson

12

1 reference

28 July 2017

Kristina Garuolienè

13

1 reference

28 July 2017

Alan Haycox

14

1 reference

28 July 2017

Silvio Garattini

15

1 reference

28 July 2017

publication date

7 June 2010

2 references

BMC Health Services Research

28 July 2017

7 February 2024

2 references

28 July 2017

7 February 2024

10

1 reference

28 July 2017

page(s)

153

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

copyright license

start time

7 June 2010

2 references

April 2022 Public Data File from Crossref

April 2022 Public Data File from Crossref

7 February 2024

1 reference

exact match

https://scigraph.springernature.com/pub.10.1186/1472-6963-10-153

0 references

cites work

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Access with evidence development in the UK: past experience, current initiatives and future potential.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Access with evidence development: the US experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Access with evidence development schemes: a framework for description and evaluation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Pharmaceutical risk-sharing agreements

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Balancing Big Pharma's books

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Value based pricing for NHS drugs: an opportunity not to be missed?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

How can we regulate medicines better?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Pharmaceutical policies: effects of financial incentives for prescribers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

How much will Herceptin really cost?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the "real world" (CRONOS project): a 36-week follow-up study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Enhancing the rational use of new medicines across European health care systems

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-153

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-153

Satisfaction guaranteed--"payment by results" for biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-153

Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-153

'Generic' biotech products: are the floodgates open? At whose expense?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Impact of better adherence to statin agents in the primary prevention of coronary artery disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

The Italian Horizon Scanning Project.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Genentech caps cost of cancer drug for some patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2906457

Current National Initiatives and Policies to Control Drug Costs in Europe

30 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-153

Bevacizumab in advanced cancer, too much or too little?

21 January 2018

1 reference

12 December 2020

Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries

1 reference

12 December 2020

Doctors to pay for patients' medicine in Germany

1 reference

12 December 2020

Risk sharing and payment by results

1 reference

12 December 2020

Patient access schemes for high-cost cancer medicines

1 reference

12 December 2020

No cure, no pay: an acceptable way of financing fertility treatments?

1 reference

12 December 2020

Value-based pricing of drugs in the UK

1 reference

12 December 2020

Risk-sharing agreements for innovative drugs: a new solution to old problems?

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

Looking beyond the headlines

1 reference

12 December 2020

Fair pricing for medicines in the UK

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6963-10-153

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference